Pharma BD Deal Intelligence
Pfizer agreed to acquire Swiss clinical-stage biotech Therachon Holding AG for $340M upfront plus up to $470M in development milestones (~$810M total); announced 13-Feb-2019 and closed 1-Jul-2019. The lead asset, TA-46 (later named recifercept), is a soluble recombinant human FGFR3 decoy designed to sequester FGF ligands extracellularly and normalize overactive FGFR3 signaling in achondroplasia — a mechanism distinct from BioMarin's CNP-analog vosoritide (VOXZOGO). Pfizer divested Therachon's secondary FGF21 short-bowel-syndrome program back to the founders. The thesis ultimately did not pan out: Pfizer's Phase 2 study of recifercept in children (NCT04638153) was terminated on 18-Nov-2022 for lack of efficacy at all tested doses (not a safety concern), and Pfizer formally discontinued the recifercept achondroplasia program on 31-Jan-2023 amid a broader pipeline thinning — leaving BioMarin's VOXZOGO uncontested among approved achondroplasia therapies.
Assessment window: 5yr post-close.